ACADIA Pharmaceuticals (NASDAQ:ACAD) CFO Thomas Aasen sold 15,000 shares of ACADIA Pharmaceuticals stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $22.48, for a total value of $337,200.00. Following the completion of the sale, the chief financial officer now directly owns 23,848 shares of the company’s stock, valued at approximately $536,103. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock opened today at $20.75 and is currently trading at $20.65. The stock showed a negative weekly performance of -14.96%.
The success of palbociclib in Phase II trials is a good news for Pfizer Inc. (NYSE:PFE) coming on the heels of the bad news of a U.S. court invalidating Pfizer’s patent for blockbuster drug Celebrex. Pfizer Inc. (NYSE:PFE) stock opened at $31.26, in current trading session and currently is at $31.33, by gaining 0.42%.The 52 week range of $27.12-$32.96. Company’s market capitalization is $200.31 billion.
The latest proposal by Jazz Pharmaceuticals (NASDAQ:JAZZ) offers around $20 per share of Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) which is almost 150% higher than the current trading range of the stock. The major cause of interest for this acquisition is the drug used for treatment of leukemia called Iclusig. But the $3.7 billion acquisition deal has not been done yet and the experts say that the possibilities are less, albeit not impossible. Incidentally, the deal amount is almost half the market cap of Jazz Pharmaceuticals (NASDAQ:JAZZ). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock is currently trading at $7.32 .The EPS of the stock is -1.49. Company’s market capitalization is $1.36 billion.
MannKind Corporation (NASDAQ:MNKD) has waited for seven years and got two complete response letters with FDA rejecting the drug approval for Afrezza. For the first rejection FDA cited that Mannkind has used two different generations of Medtone inhalers for studies. FDA said that more study and testing are required to validate bioequivalence of two different inhalers used. Rejection was very obvious that time as FDA has this street rule for all medicines up for approval. MannKind Corporation (NASDAQ:MNKD) stock opened the session at $6.50, and now is at $6.36. The 52 week range of the MNKD stock remained $3.70-$8.70 and the day range was $6.32-$6.50.
Leave a Reply